James W. Green - Aug 17, 2023 Form 4 Insider Report for HARVARD BIOSCIENCE INC (HBIO)

Role: Chief Executive Officer, Director
Signature: /s/ David Sirois, by power of attorney
Stock symbol: HBIO
Transactions as of: Aug 17, 2023
Transactions value $: $109,500
Form type: 4
Date filed: 8/21/2023, 04:06 PM
Previous filing: Jun 13, 2023
Next filing: Jan 3, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HBIO	Common Stock	Purchase	$110K	+25K	+0.88%	$4.38	2.86M	Aug 17, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was executed in multiple trades at prices ranging from $4.35 to $4.40, inclusive. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2	Includes (a) 353,140 restricted stock units that will vest in three equal installments on December 29, 2023, 2024 and 2025, (b) 104,691 restricted stock units that will vest in two equal installments on December 29, 2023 and 2024, (c) 64,899 restricted stock units that will vest on December 29, 2023, (d) 54,535 restricted stock units that will vest on December 29, 2023, (e) 671,649 restricted stock units with performance based vesting conditions tied to relative total shareholder return and (f) 1,613,765 shares of common stock beneficially owned by the Reporting Person.

Content

This transaction was executed in multiple trades at prices ranging from $4.35 to $4.40, inclusive. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Includes (a) 353,140 restricted stock units that will vest in three equal installments on December 29, 2023, 2024 and 2025, (b) 104,691 restricted stock units that will vest in two equal installments on December 29, 2023 and 2024, (c) 64,899 restricted stock units that will vest on December 29, 2023, (d) 54,535 restricted stock units that will vest on December 29, 2023, (e) 671,649 restricted stock units with performance based vesting conditions tied to relative total shareholder return and (f) 1,613,765 shares of common stock beneficially owned by the Reporting Person.